Export Data And Price Of Methoxypolyethylene Glycol , www.eximpulse.com Eximpulse Services is the place where you can find the recent and updated Trade intelligence report of Methoxypolyethylene Glycol Export Data. Whole information is based on updated Export shipment data of Indian Customs. All the compilation is done on the basis of All India ports data and has been done on daily basis. This helps you to get all India Methoxypolyethylene Glycol Export data. You can find previous two days Methoxypolyethylene Glycol Export data on Eximpulse Services. Methoxypolyethylene Glycol Export data can be useful in different kind of analysis such as: Export price, Quantity, market scenarios, Price trends, Duty optimization and many more. Some Sample Shipment records for Methoxypolyethylene Glycol Export Data of India are mentioned above. Further for Free sample and pricing of detailed reports contact on [email protected] Data post 2012 as per Notification No.18/2012 - Customs(N.T.) and does not have ...

TY - JOUR. T1 - Accelerated blood clearance phenomenon upon repeated injection of peg-modified pla-nanoparticles. AU - Ishihara, Tsutomu. AU - Takeda, Miho. AU - Sakamoto, Haruka. AU - Kimoto, Ayumi. AU - Kobayashi, Chisa. AU - Takasaki, Naoko. AU - Yuki, Kanae. AU - Tanaka, Ken Ichiro. AU - Takenaga, Mitsuko. AU - Igarashi, Rie. AU - Maeda, Taishi. AU - Yamakawa, Naoki. AU - Okamoto, Yoshinari. AU - Otsuka, Masami. AU - Ishida, Tatsuhiro. AU - Kiwada, Hiroshi. AU - Mizushima, Yutaka. AU - Mizushima, Tohru. PY - 2009/10/1. Y1 - 2009/10/1. N2 - Purpose: We recently developed prostaglandin E1 (PGE 1)-encapsulated nanoparticles, prepared with a poly(lactide) homopolymer (PLA, Mw∈=∈17,500) and monomethoxy poly(ethyleneglycol)- PLA block copolymer (PEG-PLA) (NP-L20). In this study, we tested whether the accelerated blood clearance (ABC) phenomenon is observed with NP-L20 and other PEG-modified PLA-nanoparticles in rats. Methods: The plasma levels of PGE 1 and anti-PEG IgM antibody were determined ...

We have explored the concept of using the bacterial enzyme thiaminase to disrupt energy metabolism in cancer. To optimize the biological and pharmacologic properties of this enzyme, we studied the effects of modifying it with the addition of linear polyethylene glycol chains of various sizes, a common technique that can increase plasma retention time and reduce immunogenicity of foreign proteins. Figure 1 demonstrates that the protein was successfully modified by these PEG chains of various lengths. For most of the subsequent studies we focused on the intermediate, 5k-PEG modified thiaminase enzyme in comparison with native enzyme.. We initially hypothesized that thiaminase worked through an extracellular mechanism of action, by catabolizing extracellular thiamine and causing acute thiamine starvation. Indeed, Fig. 2 shows that both native and 5k-PEG thiaminase are very potent in the catabolism of thiamine, achieving a 100-fold reduction of thiamine in medium at concentrations of 0.0001 ...

Pegylated interferon alpha 2b is used in the treatment of chronic hepatitis b virus (hbv) infection,chronic hepatitis c virus (hcv) infection,multiple myeloma(blood cancer),follicular lymphoma,hairy cell leukemia.get complete information about pegylated interferon alpha 2b including usage, side effects, drug interaction, expert advice along with medicines associated with pegylated interferon alpha 2b at 1mg.com

Find everything you need to know about Mircera (Epoetin Beta And Methoxy Polyethylene Glycol), including what it is used for, warnings, reviews, side effects, and interactions. Learn more about Mircera (Epoetin Beta And Methoxy Polyethylene Glycol) at EverydayHealth.com.

Get Details of Polyethylene Glycols Manufacturers,Polyethylene Glycols Suppliers,Polyethylene Glycols Dealers, Polyethylene Glycols Exporters, Polyethylene Glycols Traders, Polyethylene Glycols Producers, Polyethylene Glycols Wholesalers, Polyethylene Glycols Companies

email protected] Recommended for excipient applications, topical creams, lotions, personal care products, and solid oral dose. Polyethylene Glycol 6. Product Information Table of contents 3 4 6 Introduction. Polyethylene Glycol 8000, NF acts as a lubricant, coating the surfaces in aqueous and non-aqueous environments. It is also used to empty the bowels before a colonoscopy. MiraLAX Laxative Powder for Gentle Constipation Relief, #1 Dr. Polyethylene glycol 6,000. polyethylene glycol standard set mp 400-40000 polyethylene glycol, diglycidyl bisphenol a polymer polyethylene glycol/polyethylene oxide standard readycal set mp 500-2740000. chemBlink provides information about CAS # 9005-08-7, Polyethylene glycol distearate, AM 112, AM 113, Atmer 122, Atmer 123, Atmos 150, Atmul 124, Atmul 67, Atmul P. After a short sample clean-up, carbon-oxygen linkages were partially cleaved with 0. National regulations Germany AwSV/VwVwS Annex reference : Water hazard class (WGK) 1, slightly hazardous to water ...

The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models.

Source Text: English CARBOWAX Polyethylene Glycols (PEGs) and CARBOWAX Methoxypolyethylene Glycols (MPEGs) are a family of watersoluble linear polymers formed by the addition reaction of ethylene oxide to an ethylene glycol equivalent. The general formula for polyethylene glycol is: H-(OCH2CH2)n-OH and for methoxypolyethylene glycol: CH3-(OCH2CH2)n-OH where n is the average number of repeating oxyethylene groups. […]. Read More. ...

Page contains details about doxorubicin-loaded phospholipid-polyethylene glycol-modified oxidized single-walled nanotubes . It has composition images, properties, Characterization methods, synthesis, applications and reference articles : nano.nature.com

heparin drug combination ethyleneglycol monosalicylate escin: combination of aescin, heparin & ethyleneglycol monosalicylate used in topical treatment of edema, hematoma

Under the trade name Mircera, Roche Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) in January 2008 to market a continuous erythropoiesis receptor activator (methoxy polyethylene glycol-epoetin beta) for the treatment of anemia in patients with chronic kidney disease, including in those undergoing dialysis.[1] (Patent disputes between Amgen, which owns several patents relating to recombinant EPO variants, and Roche are blocking distribution of Mircera in the U.S. This issue appears to have been resolved since Fresenius Medical dialysis clinics in the US are now administering this drug.) Methoxy polyethylene glycol-epoetin beta had been approved by the European Commission in August 2007, and was made available in Europe at the start of 2008.. In terms of its structure, Mircera is similar to the previous synthetic EPO drugs, except that it is connected to a chemical called polyethylene glycol (PEG), which makes it last longer in the body. According to Roche, the ...

Export Data And Price Of Polyethylene Glycol , www.eximpulse.com Eximpulse Services is the place where you can find the recent and updated Trade intelligence report of Polyethylene Glycol Export Data. Whole information is based on updated Export shipment data of Indian Customs. All the compilation is done on the basis of All India ports data and has been done on daily basis. This helps you to get all India Polyethylene Glycol Export data. You can find previous two days Polyethylene Glycol Export data on Eximpulse Services. Polyethylene Glycol Export data can be useful in different kind of analysis such as: Export price, Quantity, market scenarios, Price trends, Duty optimization and many more. Some Sample Shipment records for Polyethylene Glycol Export Data of India are mentioned above. Further for Free sample and pricing of detailed reports contact on [email protected] Data post 2012 as per Notification No.18/2012 - Customs(N.T.) and does not have names of Indian companies and Foreign ...

Table of Contents for Global Methoxy Polyethylene Glycol (MPEG) Market by Manufacturers, Countries, Type and Application, Forecast to 2022 by Global Info Research Available at market-research-reports.com.

Doctors give trusted answers on uses, effects, side-effects, and cautions: Dr. Weisberger on methoxy polyethylene glycol epoetin beta dosage: It depends on clinical scenario . Metoprolol for instance is twice per day unless is long acting metoprolol succinate. Digoxin is once per day. The rest of drugs varies.

Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14 ...

Press Release issued Dec 8, 2016: Polyethylene glycol (PEG) is one of the most frequently used non-ionic polymers in polymer-based drug delivery and other bioactivities. Since polyethylene glycol has high aqueous solubility, it is considered for pro-drug conjugation. This appreciative status and use of PEGlycation technology in biotechnological and pharmaceutical applications has led to many progressive steps in the medical field. The existent scientific literature testifies for the various applications of polymers derived from polyethylene glycol (PEGs). The collective experience surrounding this material and relief provided by governing authorities around the world regarding its usage will lead to its increased usage in many medical device applications and drugs, which in turn will expand the market for polyethylene glycol in research and development areas. Better opportunities are predicted for the polyethylene glycol market in a range of applications such as diagnostics areas and drug development,

This is an open-label (all the people know the identity of the intervention), single arm (study will be conducted in a single group) clinical study, to evaluate the safety, tolerability and efficacy of TMC435 along with pegylated interferon alpha-2a (PegIFNα-2a) and ribavirin (RBV) triple therapy in adult chronic hepatitis C (CHC) genotype-1 infected patients who are co-infected with human immunodeficiency virus-type 1 (HIV-1). The study consists of 3 phases, screening phase (Week -6), treatment phase, and a follow-up phase (up to 24 weeks). In the treatment phase, patients will be classified based on their experience with previous hepatitis C virus (HCV) treatment as follows: 1) HCV treatment-naive (patients who never received medication for the treatment of HCV); 2) prior HCV relapsers (patients who received at least 24 weeks of a PegIFNα-2a and RBV-based therapy and relapsed within 1 year after the last medication intake); and 3) prior HCV non-responders (can be further classified as, null ...

This is an open-label (all the people know the identity of the intervention), single arm (study will be conducted in a single group) clinical study, to evaluate the safety, tolerability and efficacy of TMC435 along with pegylated interferon alpha-2a (PegIFNα-2a) and ribavirin (RBV) triple therapy in adult chronic hepatitis C (CHC) genotype-1 infected patients who are co-infected with human immunodeficiency virus-type 1 (HIV-1). The study consists of 3 phases, screening phase (Week -6), treatment phase, and a follow-up phase (up to 24 weeks). In the treatment phase, patients will be classified based on their experience with previous hepatitis C virus (HCV) treatment as follows: 1) HCV treatment-naive (patients who never received medication for the treatment of HCV); 2) prior HCV relapsers (patients who received at least 24 weeks of a PegIFNα-2a and RBV-based therapy and relapsed within 1 year after the last medication intake); and 3) prior HCV non-responders (can be further classified as, null ...

POLYETHYLENE GLYCOLS Explanation Includes polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, polyethylene glycol 1000, polyethylene glycol 1500, polyethylene glycol 1540, polyethylene glycol 4000, polyethylene glycol 6000, polyethylene glycol 9000, and polyethylene glycol 10 000.

In the interest of creating readily transfusable blood, we have developed a method of covalently bonding methoxy polyethylene gylcol (mPEG) to the erythrocyte membrane to mask antigens which would otherwise cause immunorejection in unmatched blood tr

Sustained Virological Response to Pegylated Interferon Alfa-2b (PegIntron) with or without Ribavirin Predicts Continued Response through 5 Years Sustained virological response (SVR), or continued undetectable HCV viral load 24 weeks after completion of interferon-based therapy, is widely regarded as a cure for chronic hepatitis C.. As reported at the recent Digestive Disease Week 2008 conference in San Diego, Karen Lindsay and an international team of colleagues conducted a study to confirm whether SVR predicts long-term (, 5 years) HCV clearance in adults treated with pegylated interferon, as has already been demonstrated for conventional interferon.. The present analysis included 567 adult chronic hepatitis C patients from 2 previously published clinical trials (Lindsay et al, Hepatology 2001, 34:395-403; Manns et al, Lancet 2001, 358:958-965) who were treated with pegylated interferon alfa-2b (PegIntron) with or without ribavirin.. Participants completed the initial 24 weeks of follow-up and ...

Cooksley et al 2003 is an open-label trial, which assessed the efficacy and safety of different doses of peginterferon alfa-2a vs. interferon alfa-2a 4.5 MIU for 24 weeks of therapy followed by 24 weeks of treatment-free follow up in 194 interferon-naïve patients with chronic hepatitis B. There was a non-significant higher incidence of serious adverse events in the peginterferon alfa-2a 180μg/week group (8.6%) as compared with interferon 4.5 MIU /three times a week group (4%). The most common causes of SAEs were gastrointestinal disorders and infections. There was no difference in virologic or immunologic outcomes (such as loss of DNA or seroconversion) between peginterferon alfa-2a 180μg/wk and interferon alfa-2a 4.5 MIU group. The basis of choosing 180μg/week dose as the recommended dose is not clear since the efficacy in terms of surrogate outcome measures did not differ among the different peginterferon regimens (90, 180 and 270μg/week) and the number of patients who required dose ...

China High Purity Polyethylene Glycol 4000, Find details about China Polyethylene Glycol, Top Quality Peg- 4000 from High Purity Polyethylene Glycol 4000 - ANSHAN HENGTAI PHARMACEUTICAL EXCIPIENTS MANUFACTURING CO., LTD

TY - JOUR. T1 - Injectable cartilage using polyethylene oxide polymer substrates. AU - Sims, C. Derek. AU - Butler, Peter E.M.. AU - Casanova, Rene. AU - Lee, Betty T.. AU - Randolph, Mark A.. AU - Lee, W. P.Andrew. AU - Vacanti, Charles A.. AU - Yaremchuk, Michael J.. PY - 1996/10. Y1 - 1996/10. N2 - This study demonstrates that polyethylene oxide gels, which are biocompatible and biodegradable synthetic polymers, can be utilized for the encapsulation of isolated chondrocytes and maintenance of three-dimensional spatial support for new tissue development. Chondrocytes isolated from the glenohumeral and humeroradioulnar joints of a calf were added to a 20% polyethylene oxide solution in Hams F-12 medium to generate a final cellular density of 10 x 106/ml. The polymer-chondrocyte constructs were injected through a 22-gauge needle in 500-μl aliquots subcutaneously in 12 nude mice and incubated for 6 and 12 weeks in vivo. Histologic and biochemical analyses including deoxyribonucleic acid and ...

Polyethylene Glycol,Polyethylene glycol,Polyethylene glycol. Polyethylene glycol ( PEG) is a polyether compound with many applications, from industrial

Get a FREE polyethylene Glycol Powder coupon and drug savings card and save up to 80% or more on polyethylene Glycol Powder. Use your polyethylene Glycol Powder coupon at over 60,000 USA pharmacies.

As not all patients achieve a sustained response with the standard duration of interferon-based therapy, a current focus of research is to identify ways of increasing the post-treatment response rate to peginterferon alfa-2a. Early studies have shown that additional benefits can be obtained by HBeAg-negative patients when the duration of conventional interferon therapy is extended beyond 1 year.6,7 A pilot study highlighted that the advantages of extension therapy initially observed with conventional interferon were also apparent following treatment with peginterferon alfa-2a.8 It is possible that the pattern of HBsAg decline during treatment may help identify patients for whom extended therapy should be ...

The 24-week analysis from this ongoing 48-week phase IIb clinical trial in treatment-naive HCV patients included data from the following five randomized treatment arms, all involving dosing regimens of valopicitabine, administered once-daily, in combination with pegylated interferon alfa-2a (Pegasys) 180 _g per week: (A, n=34) pegylated interferon beginning on day 8 plus valopicitabine ramping from 400 mg to 800 mg beginning at day 29-32, followed by dosing at 800 mg; (B, n=34) valopicitabine 200 mg beginning on day 1 plus pegylated interferon beginning on day 8; (C, n=34) valopicitabine ramping from 400 mg to 800 mg from day 1-6, followed by dosing at 800 mg plus pegylated interferon beginning on day 8; (D, n=36) valopicitabine 800 mg beginning on day 1 plus pegylated interferon beginning on day 8; and (E, n=35) valopicitabine 800 mg plus pegylated interferon, both beginning on day 1 ...

Suppliers List, E-mail/RFQ Form, Molecular Structure, Weight, Formula, IUPAC, Synonyms for Ethyleneglycol diglycidyl ether (CAS No. 2224-15-9)

Life-threatening and fatal neuropsychiatric reactions may occur with peginterferon alfa-2b use, including suicide, suicidal ideation, homicidal ideation and depression.. Depression was reported by 59% of patients in clinical trials. Post-marketing neuropsychiatric reactions have also been reported, including hallucinations, psychosis, aggression, bipolar mania and encephalopathy. Patients taking peginterferon alfa-2b should be advised to report any of these symptoms to their health care provider, and providers should monitor their patients for these symptoms. Suicidal or homicidal ideation should result in immediate discontinuation of peginterferon alfa-2b.). Additional serious adverse events associated with peginterferon alfa-2b treatment include:. ...

Currently, micro RNA (miRNA) is considered an attractive target for therapeutic intervention. A significant obstacle to the miRNA-based treatments is the efficient delivery of miRNA to the target tissue. We have developed polyethylene glycol-modified liposomes (Bubble liposomes (BLs)) that entrap ul …

Applicated in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound. ...

TY - JOUR. T1 - Steric stabilization of poly-L-lysine/DNA complexes by the covalent attachment of semitelechelic poly[N-(2-hydroxypropyl)methacrylamide]. AU - Oupicky, David. AU - Howard, Kenneth A.. AU - Koňák, Čestmír. AU - Dash, Philip R.. AU - Ulbrich, Karel. AU - Seymour, Leonard W.. PY - 2000/7/1. Y1 - 2000/7/1. N2 - The concept of steric stabilization was utilized for self-assembling polyelectrolyte poly-L-lysine/DNA (pLL/DNA) complexes using covalent attachment of semitelechelic poly[N-(2-hydroxypropyl)methacrylamide] (pHPMA). We have examined the effect of coating of the complexes with pHPMA on their physicochemical stability, phagocytic uptake in vitro, and biodistribution in vivo. The coated complexes showed stability against aggregation in 0.15 M NaCl and reduced binding of albumin, chosen as a model for the study of the interactions of the complexes with plasma proteins. The presence of coating pHPMA had no effect on the morphology of the complexes as shown by transmission ...

1.Previous studies have indicated that the permeability of polyethyleneglycol across the human intestine is anomalously high in comparison with the permeability of sugars with similar molecular mass. In consequence it has been proposed that two or more distinct mechanisms must exist for the translocation of these classes of molecule or, alternatively, that the molecular parameter determining rate of penetration is each molecules minimum molecular dimension.. 2.The notional hydrogen-bonding capacity of a molecule correlates well with oil-water partition coefficient and also, in a variety of experimental systems, with rate of passive diffusion across biological membranes. A molecules hydrogen-bonding capacity is calculated by inspecting the structural formula and summing the individual theory-derived hydrogen-bonding capacities of the molecules functional groups.. 3.A classic set of intestinal permeability data that includes several ethyleneglycol oligomers and several sugars is re-analysed. A ...

Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound ...

Materials and cell culture. 1,2-Dioleoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, N-hexanoyl-d-erythro-sphingosine (C6), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy polyethylene glycol-2000], N-octanoyl-sphingosine-1-[succinyl(methoxy polyethylene glycol-750)] (PEG(750)-C8), N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-d-erythro-sphingosine (NBD-C6), and N,N-dimethyl-d-erythro-sphingosine (DMSph) were purchased from Avanti Polar Lipids (Alabaster, AL). N-hexanoyl-d-erythro-sphingosine [hexanoyl 6-3H] ([3H]C6) was obtained from ARC (St. Louis, MO). Primary antibodies to caveolin-1 and CD31 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and BD PharMingen (San Jose, CA), respectively. Horseradish peroxidase-conjugated goat anti-rabbit IgG and rhodamine red-X-conjugated goat anti-rat IgG secondary antibodies were obtained from Santa Cruz Biotechnology and Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA), ...

Protein PEGylation (covalent attachment of poly(ethylene glycol) or PEG to proteins) is an excellent example of a drug delivery system that improves pharmacokinetics and pharmacodynamic properties of therapeutics. However, although PEGylation is clinically proven and attracts both scientific and commercial interest, the technique is associated with many process constraints, in particular related to controlling the number of conjugated PEG chains. A novel, solid-phase PEGylation methodology was attempted to overcome the drawbacks of the commonly used solution-phase methods for preparing PEGylated products. The solid-phase PEGylation methodology involved conjugating protein onto a tethered PEG derivative attached onto a solid matrix, followed by hydrolytic cleavage of the PEG chain from the solid matrix under mild conditions to yield PEGylated protein in free solution. PEGs with molecular weights (MWs) 2000 and 4000 Da were used and a heterobifunctional PEG derivative, α-(β-alanine)-ω-carboxy ...

SINOPEG is a professional PEG Derivatives by Application manufacturer and supplier,we supply high purity -Alkyne PEGylation at best price. Inquiry now!

What is polyethylene glycol 3350? Learn about polyethylene glycol 3350 side effects, how to take polyethylene glycol 3350 and more.

Abstract The purpose of this review article is to describe the properties and applications of polyethylene oxide. Polyethylene oxide is a biocompatible polymer, which is marketed as

Recently, a new radioimmunoassay--the polyethylene glycol (PEG) assay--was introduced to measure antibodies to double-stranded (ds) DNA. In this method, polyethylene glycol precipitation of formed 3H-DNA/antiDNA complexes is used instead of the ammonium sulfate precipitation used in the Farr assay. …

China Sodium Lauryl Ether Sulfate CAS No 68585-34-2 with Great Quality, Find details about China Sodium Lauryl Ether Sulfate, Sodium Laureth Sulfate from Sodium Lauryl Ether Sulfate CAS No 68585-34-2 with Great Quality - Dalian Chem Imp.& Exp. Group Co., Ltd.

China Sodium Lauryl Ether Sulfate 70%, SLES 70%, Find details about China Sodium Lauryl Ether Sulfate, Chemicals from Sodium Lauryl Ether Sulfate 70%, SLES 70% - Zouping Changshan Zefeng Fertilizer Co., Ltd.

sodium lauryl ether sulfate sles 70%, CAS No. 68585-34-2 Specification sodium lauryl ether sulfate SLES CAS NO. 68585-34-2 C12H26Na2O5S best price Product Name Sodium lauryl ether sulfate Synonyms SODIUM LAURYL ETHER SULFATE;NAXOLATE...

Fabrication and Properties of Polyethylene Glycol-Modified Wood Composite for Energy Storage and Conversion. Yun Li,a Xianjun Li,a,* Dandan Liu,b Xiyi Cheng,a Xia He,a Yiqiang Wu,a Xingong Li,a and Qiongtao Huang c. Green fir wood (Pseudotsuga menziesii) was modified with polyethylene glycol (PEG) to produce wood composites for energy storage and conversion. The PEG-modified wood composites were evaluated based on their dimensional stability, durability, and thermal properties by various analytical methods. The differential scanning calorimetry (DSC) results showed the melting temperature and the latent heat of the phase change material (PCM) composite were 26.74 °C and 73.59 J/g, respectively. Thermal cycling tests and thermogravimetric analysis confirmed the composite exhibited good thermal stability, reliability, and chemical stability. All treated specimens were free from noticeable defects, and the addition of a surface varnish coating prevented PEG from leaching. The PEG-modified ...

Looking for online definition of polyethylene glycol electrolyte for gastrointestinal lavage solution in the Medical Dictionary? polyethylene glycol electrolyte for gastrointestinal lavage solution explanation free. What is polyethylene glycol electrolyte for gastrointestinal lavage solution? Meaning of polyethylene glycol electrolyte for gastrointestinal lavage solution medical term. What does polyethylene glycol electrolyte for gastrointestinal lavage solution mean?

Definition of polyethylene glycol electrolyte for gastrointestinal lavage solution in the Legal Dictionary - by Free online English dictionary and encyclopedia. What is polyethylene glycol electrolyte for gastrointestinal lavage solution? Meaning of polyethylene glycol electrolyte for gastrointestinal lavage solution as a legal term. What does polyethylene glycol electrolyte for gastrointestinal lavage solution mean in law?

TY - JOUR. T1 - Synthesis of silver nanoparticles stabilized by carboxylated methoxypolyethylene glycols. T2 - the role of carboxyl terminal groups in the particle size and morphology. AU - Titkov, Alexander I.. AU - Logutenko, Olga A.. AU - Gerasimov, Evgeny Yu. AU - Shundrina, Inna K.. AU - Karpova, Elena V.. AU - Lyakhov, Nikolay Z.. N1 - Publisher Copyright: © 2019, Springer Nature B.V. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.. PY - 2019/8/15. Y1 - 2019/8/15. N2 - In this work the effect of the synthesis conditions on the size and morphology of the nanoparticles obtained via the reduction of silver ions by benzyl alcohol in the presence of carboxylated methoxypolyethylene glycols with different molecular weights (mPEG-COOH 350, containing a terminal carboxyl group, MW ~ 350 and 2-[2-(2-methoxyethoxy)ethoxy]acetic acid (MEEAA), MW ~ 200) and non-carboxylated mPEG 350 has been studied. The synthesized nanoparticles were characterized by means of X-ray diffraction (XRD), ...

Buy this report (Price 2900 USD for a single-user license) @ https://www.marketgrowthreports.com/purchase/17242744. Major Points from Table of Contents:. 1 Study Coverage. 1.1 Polyvinyl Alcohol Polyethylene Glycol Graft Copolymer Product. 1.2 Key Market Segments in This Study. 1.3 Key Manufacturers Covered. 1.4 Market by Type. 1.4.1 Global Polyvinyl Alcohol Polyethylene Glycol Graft Copolymer Market Size Growth Rate by Type. 1.5 Market by Application. 1.5.1 Global Polyvinyl Alcohol Polyethylene Glycol Graft Copolymer Market Size Growth Rate by Application. 1.6 Study Objectives. 1.7 Years Considered. 2 Executive Summary. 2.1 Global Polyvinyl Alcohol Polyethylene Glycol Graft Copolymer Production. 2.1.1 Global Polyvinyl Alcohol Polyethylene Glycol Graft Copolymer Revenue 2014-2026. 2.1.2 Global Polyvinyl Alcohol Polyethylene Glycol Graft Copolymer Production 2014-2026. 2.1.3 Global Polyvinyl Alcohol Polyethylene Glycol Graft Copolymer Capacity 2014-2026. 2.1.4 Global Polyvinyl Alcohol Polyethylene ...

The purpose of this study is to determine if 24 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and 12 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and Daclatasvir will be safe and effective for treatment of hepatitis C compared to 24 weeks of treatment with Pegylated Interferon Alfa-2a plus Ribavirin.. ...

A combination of weekly pegylated interferon (peginterferon) alpha and daily ribavirin represents the standard of care for the treatment of chronic hepatitis C according to current guidelines. It is not established which of the two licensed products (peginterferon alpha-2a or peginterferon alfa-2b) is most effective. We performed a systematic review of head-to-head randomized trials to assess the benefits and harms of the two treatments. We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and LILACS through July 2009. Using standardized forms, two reviewers independently extracted data from each eligible trial report. We statistically combined data using a random effects meta-analysis according to the intention-to-treat principle. We identified 12 randomized clinical trials, including 5,008 patients, that compared peginterferon alpha-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin. Overall, peginterferon alpha-2a significantly increased the number of ...

It is unknown if polyethylene glycol electrolyte solution passes through breast milk. This eMedTV page explains that no studies have been done on using polyethylene glycol electrolyte solution while breastfeeding, and why problems are probably unlikely.

Polyethylene glycol electrolyte solution is a laxative solution that increases the amount of water in the intestinal tract to stimulate bowel movements. This medication also contains potassium, sodium, and other minerals to replace electrolytes that are passed from the body in the stool. Polyethylene glycol electrolyte...

Although HCV-monoinfected patients with an HCV genotype of 1 can expect a 40-45% chance of an SVR using pegylated interferon/ribavirin, HIV/HCV-coinfected patients with genotype-1 are looking at an SVR of 14% (ACTG) to 29% (Apricot). The results in co-infected patients with genotypes 2/3 infections were encouraging with 45% (Ribavic) to 62% (Apricot) SVRs. However, it is important to note that all patients received 48 weeks of therapy. It is likely that, in order to achieve an optimal response, all genotype 2/3 HIV/HCV co-infected patients should receive 48 weeks of treatment with pegylated interferon/ribavirin.. HCV-RNA was associated with treatment outcome in Apricot, but not Ribavic. Analysis, especially for patients with genotype -1 co-infections, by baseline viral loads were not available. It is likely that those with high HCV viral loads (800,000 iu/l) will have poor responses. Although, baseline CD4 counts have been shown to affect response to therapy, patients in both Ribavic and Apricot ...

TY - JOUR. T1 - Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B. T2 - an updated systematic review and economic evaluation. AU - Shepherd, J. AU - Jones, Jeremy. AU - Baxter, L. AU - Gospodarevskaya, E. AU - Hartwell, D. AU - Harris, P. AU - Price, A. PY - 2009/7. Y1 - 2009/7. N2 - OBJECTIVE: To update and extend a 2006 report on the clinical effectiveness and cost-effectiveness of adefovir dipivoxil (ADV) and pegylated interferon alpha (PEG-alpha) for the treatment of chronic hepatitis B (CHB).DATA SOURCES: Thirteen bibliographic databases were searched including MEDLINE, EMBASE and the Cochrane Library. Searches were run from the beginning of 2005 to September 2007.REVIEW METHODS: For the clinical effectiveness review, randomised controlled trials (RCTs) comparing ADV, PEG-alpha-2a and PEG-alpha-2b with currently licensed treatments for CHB, including non-pegylated interferon alpha (IFN-alpha) and lamivudine (LAM), were included. Outcomes included ...

BACKGROUND: Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether pegylated interferon alfa-2b can facilitate prolonged exposure while maintaining tolerability. METHODS: 1256 patients with resected stage III melanoma were randomly assigned to observation (n=629) or pegylated interferon alfa-2b (n=627) 6 mug/kg per week for 8 weeks (induction) then 3 mug/kg per week (maintenance) for an intended duration of 5 years. Randomisation was stratified for microscopic (N1) versus macroscopic (N2) nodal involvement, number of positive nodes, ulceration and tumour thickness, sex, and centre. Randomisation was done with a minimisation technique. The primary endpoint was recurrence-free survival. Analyses were done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00006249. FINDINGS: All randomised patients were included in the primary efficacy analysis. 608 patients in the interferon group and ...

BACKGROUND Data are limited on the efficacy and safety of pegylated interferon plus ribavirin for patients with hepatitis C virus genotype 1 (HCV-1) receiving hemodialysis. OBJECTIVE To compare the efficacy and safety of combination therapy with pegylated interferon plus low-dose ribavirin and pegylated interferon monotherapy for treatment-naive patients with HCV-1 receiving hemodialysis. DESIGN Open-label, randomized, controlled trial. (ClinicalTrials.gov: NCT00491244). SETTING 8 centers in Taiwan. PATIENTS 205 treatment-naive patients with HCV-1 receiving hemodialysis. INTERVENTION 48 weeks of pegylated interferon-α2a, 135 µg weekly, plus ribavirin, 200 mg daily (n = 103), or pegylated interferon-α2a, 135 µg weekly (n = 102). MEASUREMENTS Sustained virologic response rate and adverse event-related withdrawal rate. RESULTS Compared with monotherapy, combination therapy had a greater sustained virologic response rate (64% vs. 33%; relative risk, 1.92 [95% CI, 1.41 to 2.62]; P | 0.001).

Looking for online definition of peginterferon alfa-2a in the Medical Dictionary? peginterferon alfa-2a explanation free. What is peginterferon alfa-2a? Meaning of peginterferon alfa-2a medical term. What does peginterferon alfa-2a mean?

Antibodies against polyethylene glycol (PEG) in healthy subjects raise concerns about the efficacy of pegylated drugs. We evaluated the prevalence of antibodies against PEG among patients with acute lymphoblastic leukemia (ALL) prior to and/or immediately after their first dose of pegylated E.coli asparaginase (PEG-ASNase). Serum samples of 701 children, 673 with primary ALL, 28 with relapsed ALL, and 188 adults with primary ALL were analyzed for anti-PEG IgG and IgM. Measurements in 58 healthy infants served as reference to define cut-points for antibody-positive and -negative samples. Anti-PEG antibodies were detected in ALL patients prior the first PEG-ASNase with a prevalence of 13.9% (anti-PEG IgG) and 29.1% (anti-PEG IgM). After administration of PEG-ASNase the prevalence of anti-PEG antibodies decreased to 4.2% for anti-PEG IgG and to 4.5% for anti-PEG IgM. Pre-existing anti-PEG antibodies did not inhibit PEG-ASNase activity but significantly reduced PEGASNase activity levels in a ...

BioMed Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies covering a wide range of subjects in life sciences and medicine. The journal is divided into 55 subject-specific sections.

Medscape - Bowel prep dosing for MoviPrep, PlenVu (polyethylene glycol/electrolytes/sodium ascorbate/ascorbic acid), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.

TY - JOUR. T1 - Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®). T2 - Possible role in hypersensitivity reactions. AU - Chanan-Khan, Asher. AU - Szebeni, J.. AU - Savay, S.. AU - Liebes, L.. AU - Rafique, N. M.. AU - Alving, C. R.. AU - Muggia, F. M.. PY - 2003/9/1. Y1 - 2003/9/1. N2 - Background: Pegylated liposomal doxorubicin (Doxil®) has been reported to cause immediate hypersensitivity reactions (HSRs) that cannot be explained as IgE-mediated (type I) allergy. Previous in vitro and animal studies indicated that activation of the complement (C) system might play a causal role in the process, a proposal that has not been tested in humans to date. Patients and methods: Patients with solid tumors (n = 29) treated for the first time with Doxil were evaluated for HSRs and concurrent C activation. HSRs were classified from mild to severe, while C activation was estimated by serial measurement of plasma C terminal complex (SC5b-9) levels. Increases in ...

Synonyms for adenosine deaminase conjugated with polyethylene glycol in Free Thesaurus. Antonyms for adenosine deaminase conjugated with polyethylene glycol. 2 words related to adenosine: biochemistry, nucleoside. What are synonyms for adenosine deaminase conjugated with polyethylene glycol?

Methoxy polyethylene glycol-epoetin beta injection causes the bone marrow to produce red blood cells. If the body does not produce enough red blood cells, severe anemia can occur. This often occurs in people with chronic kidney failure whose kidneys are not working properly. This medicine is available only with your doctors prescription. This product is available in the following dosage forms:. ...

TY - JOUR. T1 - Effect of hemoglobin (Hb) maintenance of subcutaneous (SC) or intravenous (IV) C. E. R. A. (Continuous Erythropoietin Receptor Activator) in chronic kidney disease (CKD) patients not on dialysis. AU - Yuzawa, Yukio. AU - Hotta, Osamu. AU - Suzuki, Hiromichi. AU - Oishi, Tetsuya. AU - Mochizuki, Takahiro. AU - Wakasa, Mikio. AU - Uda, Susumu. AU - Kanno, Yutaka. AU - Horikawa, Kazuhiro. AU - Hara, Soshun. AU - Ichida, Shizunori. AU - Morozumi, Kunio. AU - Shimizu, Hideaki. AU - Tsuyuki, Mikito. AU - Tamai, Hirofumi. AU - Asada, Hiroaki. AU - Naruse, Tomohiko. AU - Inaguma, Daijyo. AU - Suzuki, Satoshi. AU - Kasuga, Hirotake. AU - Ishimura, Eiji. AU - Imai, Enyu. AU - Yamauchi, Atsushi. AU - Saika, Yasushi. AU - Saito, Yoshihiko. AU - Taki, Masafumi. AU - Kawanishi, Hideki. AU - Minakuchi, Jun. AU - Yuasa, Kenji. AU - Miyake, Susumu. AU - Takeda, Kazuhito. AU - Yasunaga, Chikao. AU - Okuda, Seiya. AU - Nakamoto, Masahiko. AU - Saito, Takao. AU - Tsuruya, Kazuhiko. AU - Hirakata, ...

Glycol: any of a class of organic chemicals characterized by having separate two hydroxyl (-OH) groups, contribute to high water solubility, hygroscopicity and reactivity with many organic compounds, on usually linear and aliphatic carbon chain. The general formula is CnH2n(OH)2 or (CH2)n(OH)2. The wider meaning names include diols, dihydric alcohols, and dihydroxy alcohols. Polyethylene glycols and polypropylene glycols are sometimes called polyglycols which are derived by polymerization of ethylene oxide and propylene oxide respectively. Polyethylene glycols are water-soluble at all molecular weights, but polypropylene glycols become increasingly less water-soluble at high molecular weights. Ethylene glycol, HOCH2CH2OH, is the simplest member of the glycol family. Mono-, di- and triethylene glycols are the first three members of a homologous series of dihydroxy alcohols. They are colourless, essentially odourless stable liquids with low viscosities and high boiling points. Ethylene glycol is a ...

Glycol: any of a class of organic chemicals characterized by having separate two hydroxyl (-OH) groups, contribute to high water solubility, hygroscopicity and reactivity with many organic compounds, on usually linear and aliphatic carbon chain. The general formula is CnH2n(OH)2 or (CH2)n(OH)2. The wider meaning names include diols, dihydric alcohols, and dihydroxy alcohols. Polyethylene glycols and polypropylene glycols are sometimes called polyglycols which are derived by polymerization of ethylene oxide and propylene oxide respectively. Polyethylene glycols are water-soluble at all molecular weights, but polypropylene glycols become increasingly less water-soluble at high molecular weights. Ethylene glycol, HOCH2CH2OH, is the simplest member of the glycol family. Mono-, di- and triethylene glycols are the first three members of a homologous series of dihydroxy alcohols. They are colourless, essentially odourless stable liquids with low viscosities and high boiling points. Ethylene glycol is a ...

0034] Suitable non-limiting examples to polyethyleneglycols and polypropyleneglycols are PEG-4, PEG-6, PEG-7, PEG-8, PEG-9, PEG-10, PEG-12, PEG-14, PEG-16, PEG-18, PEG-20, PEG-32, PEG-33, PEG-40, PEG-45, PEG-55, PEG-60, PEG-75, PEG-80, PEG-90, PEG-100, PEG-135, PEG-150, PEG-180, PEG-180, PEG-200, PEG-220, PEG-240, PEG-350, PEG-400, PEG-450, PEG-500, PEG-800, PEG-2M, PEG-5M, PEG-7M, PEG-9M, PEG-14M, PEG-20M, PEG-23M, PEG-25M, PEG-45M, PEG-65M, PEG-90M, PEG-115M, PEG-160M, PEG-180M, PPG-3, PPG-7, PPG-9, PPG-12, PPG-13, PPG-15, PPG-16, PPG-17, PPG-20, PPG-26, PPG-30, PPG-33, PPG-34, PPG-51, PPG-52, and PPG-69. Preferred are PEG-10, PEG-12, PEG-14, PEG-16, PEG-18, PEG-20, PEG-32, PEG-33, PEG-40, PEG-45, PEG-55, PEG-60, PEG-75, PEG-80, PEG-90, PEG-100, PEG-135, PEG-150, PPG-12, PPG-13, PPG-15, PPG-16, PPG-17, PPG-20, PPG-26, PPG-30, PPG-33, PPG-34, PPG-51, PPG-52, and PPG-69. More preferred are PEG-12, PEG-14, PEG-16, PEG-18, PEG-20, PEG-32, PEG-33, PEG-40, PEG-45, PEG-55, PEG-60, PEG-75, PEG-80, ...

TY - JOUR. T1 - Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-α2a plus ribavirin treatment. AU - Massanella, Marta. AU - Tural, Cristina. AU - Papagno, Laura. AU - Garcia, Elisabet. AU - Jou, Antoni. AU - Bofill, Margarita. AU - Autran, Brigitte. AU - Clotet, Bonaventura. AU - Blanco, Julià. PY - 2010/1/1. Y1 - 2010/1/1. N2 - Background: We evaluated the effect of different doses of pegylated interferon (PEG-IFN)-α2a/ribavirin (RBV) on several T-cell activation markers in HIV-HCV-coinfected patients and their relationship with changes in plasma HCV RNA. Methods: Frozen peripheral blood mononuclear cells (PBMCs) from 22 patients receiving two different PEG-IFN-α2a schedules were analysed by six-colour flow cytometry. Cell-surface expression of CD38 was quantified. HIV and HCV viral loads, as well as absolute CD4+ and CD8+ T-cell counts, were recorded during the follow up (72 weeks). Results: PEG-IFN-α2a/RBV treatment decreased the absolute numbers of ...

BARCELONA, Spain, Apr 19, 2012 (BUSINESS WIRE) --Gilead Sciences, Inc. (Nasdaq:GILD) today announced interim data from a Phase 2 trial (ATOMIC) examining a 12-week course of treatment with the once-daily nucleotide GS-7977 plus pegylated interferon (Peg-IFN) and ribavirin (RBV) in treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. The study found that 90 percent of patients (n=47/52, missing data equals failure analysis) achieved a 12-week sustained virologic response (SVR12), defined as maintaining undetectable viral load (HCV RNA ,25 IU/mL) 12 weeks after the completion of therapy. These findings will be presented today during an oral session at the 47th Annual Meeting of the European Association for the Study of the Liver (International Liver Congress 2012) in Barcelona, Spain. These data suggest that this GS-7977-based regimen could offer most patients with genotype 1 a simple, short, three-month course of treatment with very high cure rates, said Kris ...

Three PEG molecules (PEG-methacrylate, -diacrylate and -dimethacrylate) were incorporated into galactose-based polyacrylate hydrogels and their relative abilities to reduce non-specific protein adsorption in immunoassays were determined. Highly crosslinked hydrogels containing amine-terminated functionalities were formed and used to covalently attach antibodies specific for staphylococcal enterotoxin B (SEB). Patterned arrays of immobilized antibodies in the PEG-modified hydrogels were created with a PDMS template containing micro-channels for use in sandwich immunoassays to detect SEB. Different concentrations of the toxin were applied to the hydrogel arrays, followed with a Cy3-labeled tracer antibody specific for the two toxins. Fluorescence laser scanning confocal microscopy of the tracer molecules provided both qualitative and quantitative measurements on the detection sensitivity and the reduction in non-specific binding as a result of PEG incorporation. Results showed the PEG-modified hydrogel

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naïve patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800-1400 mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44.2% of Peg-IFNα-2a-treated patients and in 51.2% of Peg-IFNα-2b-treated patients (intention-to-treat; P = 0.139). Age, fibrosis stage and genotype 2 and 3 were independently associated with SVR by multivariate analysis. Analysing by gender, the difference in SVR between PEG-IFNα types was not significant in men ...

286578264 - EP 1258560 A1 2002-11-20 - Use of hydrophobically modified polyaminamides with polyethylene glycol esters in paper products - The present invention uses hydrophobically modified polyaminamide with standard wet strength agent to produce a softer and more absorbent paper material. The hydrophobically modified polyaminamide is substantive to cellulosic fibers, thus is able to carry polyethylene glycol esters or ethers, a non-substantive material to cellulosic fiber as stable complexes, into the paper product.[origin: EP1258560A1] The present invention uses hydrophobically modified polyaminamide with standard wet strength agent to produce a softer and more absorbent paper material. The hydrophobically modified polyaminamide is substantive to cellulosic fibers, thus is able to carry polyethylene glycol esters or ethers, a non-substantive material to cellulosic fiber as stable complexes, into the paper product.

TY - JOUR. T1 - Drug Delivery Nanocarriers from a Fully Degradable PEG-Conjugated Polyester with a Reduction-Responsive Backbone. AU - Yameen, Basit. AU - Vilos, Cristian. AU - Choi, Won Il. AU - Whyte, Andrew. AU - Huang, Jining. AU - Pollit, Lori. AU - Farokhzad, Omid C.. PY - 2015/8/1. Y1 - 2015/8/1. N2 - The remarkably high intracellular concentration of reducing agents is an excellent endogenous stimulus for designing nanocarriers programmed for intracellular delivery of therapeutic agents. However, despite their excellent biodegradability profiles, aliphatic polyesters that are fully degradable in response to the intracellular reducing environment are rare. Herein, a reduction-responsive drug delivery nanocarrier derived from a linear polyester bearing disulfide bonds is reported. The reduction-responsive polyester is synthesized via a convenient polycondensation process. After conjugation of terminal carboxylic acid groups of polyester to polyethylene glycol (PEG), the resulting polymer ...

The incorporation of poly(ethylene glycol) (PEG)-conjugated lipids in lipid-based carriers substantially prolongs the circulation lifetime of liposomes. However, the mechanism(s) by which PEG-lipids achieve this have not been fully elucidated. It is believed that PEG-lipids mediate steric stabilization, ultimately reducing surface-surface interactions including the aggregation of liposomes and/or adsorption of plasma proteins. The purpose of the studies described here was to compare the effects of PEG-lipid incorporation in liposomes on protein binding, liposome-liposome aggregation and pharmacokinetics in mice. Cholesterol-free liposomes were chosen because of their increasing importance as liposomal delivery systems and their marked sensitivity to protein binding and aggregation. Specifically, liposomes containing various molecular weight PEG-lipids at a variety of molar proportions were analyzed for in vivo clearance, aggregation state (size exclusion chromatography, quasi-elastic light ...

Peginterferon alfa-2b: Find the most comprehensive real-world treatment information on Peginterferon alfa-2b at PatientsLikeMe. 4 patients with fibromyalgia, multiple sclerosis, major depressive disorder, generalized anxiety disorder, diabetes type 2, post-traumatic stress disorder, systemic lupus erythematosus, bipolar disorder, Parkinsons disease, panic disorder, rheumatoid arthritis, high blood pressure (hypertension), myalgic encephalomyelitis/chronic fatigue syndrome, persistent depressive disorder (dysthymia), amyotrophic lateral sclerosis, epilepsy, migraine, hypothyroidism, osteoarthritis, traumatic brain injury, attention deficit/hyperactivity disorder, bipolar II disorder, asthma, social anxiety disorder, high cholesterol (hypercholesterolemia), irritable bowel syndrome, idiopathic pulmonary fibrosis, gastroesophageal reflux disease, bipolar I disorder or psoriasis currently take Peginterferon alfa-2b.

TY - CHAP. T1 - Engineering well-characterized PEG-coated nanoparticles for elucidating biological barriers to drug delivery. AU - Yang,Qi. AU - Lai,Samuel K.. PY - 2017. Y1 - 2017. N2 - Poly(ethylene glycol) (PEG) coatings can substantially reduce nanoparticle uptake and clearance by immune cells as well as nonspecific interactions with the biological environment, thus potentially improving nanoparticle circulation times and biodistribution in target tissues such as tumors. Naturally, the stealth properties of PEG coatings are critically dependent on the density and conformation of surface PEG chains. However, there are significant technical hurdles to both generating sufficiently dense PEG coatings on nanoparticles and precisely characterizing their PEG grafting densities. Here, we describe methods for preparing PEGylated polymeric nanoparticles with precisely tunable PEG coatings without the use of organic solvents, quantifying PEGylation efficiency and density using a standard fluorescence ...